Risk Factors Update Summary

• The FDA review process may be extended by three months if additional data is requested. This change might result in significant delays in product approval timelines.
• We estimate approximately 83,000 new patients diagnosed with bladder cancer annually, with 80% having NMIBC. This change highlights the significant patient population at risk.
• We depend heavily on the success of our lead product candidate, detalimogene voraplasmid, currently in clinical trials. This change might result in significant market impact.
• The Company will indemnify the Executive against tax liabilities incurred in Canada and the U.S. This includes liabilities from being a Passive Foreign Investment Company.
• Our compliance with financing agreements may restrict operations, impacting flexibility and growth potential. This could lead to operational limitations affecting revenue generation.
• A new Addendum 5 to the Existing Loan Agreement has been inserted, impacting financial obligations. This change might result in increased compliance costs for the company.
• The company will pay a one-time payment of $50 thousand upon assigning the License Agreement. This change might result in increased cash outflow.
• As of October 31, 2024, the company had 57 employees, an increase from 33. This change indicates growth in operational capacity and potential for increased productivity.
• The Executive's Base Salary will continue for a twelve-month period at the rate in effect, potentially totaling $[amount] million.
• The Recovery Period for erroneously awarded Incentive-Based Compensation is defined as three fiscal years. This change might result in significant financial implications for the company.
• The Company has incurred a net loss of $55,142 million for the year ended October 31, 2024, compared to $99,917 million in 2023. This change might result in increased investor concern.
• The FDA has granted Fast Track designation for detalimogene for treating BCG-unresponsive NMIBC patients. This designation may expedite the review process but does not guarantee approval.
• The duration, costs, and timing of clinical studies for detalimogene will depend on various factors. This change might result in significant changes to development costs and timelines.
• The Company will reimburse the Executive for cross-border tax filings and related costs. This includes joining the NEXUS program and any visa-related expenses.
• The Executive's Base Salary is set at $440,000 annually, reflecting a significant commitment from the Company.
• The Company recorded $1.4 million and $1.0 million as reductions in research and development expenses for 2024 and 2023, respectively. This change might result in improved financial performance.
• The Common Shares authorized under the 2023 Plan increased by 1,946,226 on January 2, 2024. This change might result in increased equity compensation flexibility.
• The estimates of market sizes and forecasts for detalimogene's potential demand are based on complex assumptions, which may prove inaccurate. This could materially harm our business.
• The estimated percentage of high-risk NMIBC patients is now 30%, while 35% are intermediate-risk and 35% low-risk. This stratification emphasizes the varying treatment needs.
• The Executive's severance benefits include a continuation of base salary totaling $485,000 over 12 months. This ensures financial stability post-employment.
• The CR rate at three months for the pivotal cohort is now reported at 67%, down from previous estimates. This change may impact treatment expectations and strategies.
• The Company is required to pay NTC a $50 thousand annual maintenance fee, impacting cash flow. This ongoing obligation could affect future liquidity.
• We entered into a letter agreement with Investissement Quebec, agreeing to maintain operations in Québec. This may limit operational flexibility and strategic decisions.
• Any time-based equity awards will accelerate and vest during the Severance Term, enhancing executive compensation.
• The accumulated deficit increased from $199 million to $254 million, highlighting financial challenges. This change may raise concerns about the company's long-term viability and funding needs.
• The Effective Date of the new policy is set as October 2, 2023, impacting future compensation recoveries.
• The company issued options to purchase 1,643,000 Common Shares at a weighted-average exercise price of $8.69 per share. This could impact future share dilution.
• Total current assets increased significantly from $85,440 million in 2023 to $247,362 million in 2024, indicating improved liquidity.
• The Compliance Certificate and other financial reports must now be uploaded and executed via specified electronic means, enhancing operational efficiency.
• Inadequate funding or disruptions at the FDA could hinder timely product approvals, negatively impacting business operations. Recent government shutdowns have previously affected regulatory processes.
• Research and development expenses increased from $15,857 million to $38,315 million, primarily due to clinical activities for detalimogene. This increase reflects heightened operational demands.
• A one-time Sign-On Bonus of $30,000 will be awarded, contingent on completing one year of employment.
• We currently estimate approximately 83,000 new patients diagnosed with BCG-unresponsive NMIBC each year, up from 60,000. This change indicates a larger potential market.
• A one-time payment of $450 thousand is due upon regulatory approval of a Milestone Product. This change might impact future cash reserves.
• The company reported net losses of $99.9 million for the fiscal year ended October 31, 2024, compared to $55.1 million in 2023. This change reflects worsening financial performance and potential investor risk.
• The Company reported total operating expenses of $62,297 million in 2024, up from $26,060 million in 2023, raising concerns about cost management.
• The 2024 target annual bonus for the former CEO is set at $390,000. This change reflects significant executive compensation adjustments.
• General and administrative expenses rose from $9,602 million to $23,982 million, driven by increased personnel-related costs and professional fees. This change indicates growing operational complexity.
• The introduction of rationing for BCG therapy limits its use to high-risk NMIBC patients only. This change reflects the ongoing drug shortages and treatment prioritization.
• The Executive's target annual bonus of 40% will be prorated based on employment duration in 2024. This ensures fair compensation for the performance period worked.
• The definition of "Disability" now includes eligibility for long-term disability benefits, impacting executive termination rights.
• The Company had 23,197,976 common shares outstanding as of October 31, 2024, compared to 10,411,641 in 2023. This increase may influence shareholder value and market perception.
• Our cash and cash equivalents increased to $173 million from $81.5 million, enhancing liquidity. This change might improve our ability to fund ongoing projects and operations.
• The definition of "Incentive-Based Compensation" now excludes discretionary bonuses, clarifying compensation recovery criteria.
• The Transition Agreement with the former CEO includes a target annual bonus of $390,000. This change may affect executive compensation dynamics and investor perceptions.
• The implementation of the IRA may lead to reduced demand for detalimogene, if approved, due to pricing pressures. This could adversely affect revenue generation from product candidates.
• Detalimogene has received FDA Fast Track designation, expediting its development for BCG-unresponsive NMIBC with CIS, an underserved therapeutic segment. This could enhance market entry speed.
• Borrower confirms that the representations and warranties in the Amended Loan Agreement are true and correct, ensuring legal compliance and reducing risk exposure.
• The Executive's Target Annual Bonus is established at 40% of the Base Salary, incentivizing performance alignment.
• The company has adopted a Compensation Recoupment Policy to enforce mandatory clawbacks in case of financial restatements, potentially affecting executive compensation structures.
• The company recognized incremental stock-based compensation expense of $1 million due to modifications in stock option awards. This change could affect financial performance metrics.
• If terminated without Cause, the Executive will receive a 12-month salary continuation during the Severance Term.
• Cash and cash equivalents rose from $81,521 million in 2023 to $173,004 million in 2024, enhancing financial stability.
• The armed conflict in the Middle East has created volatility in global capital markets, potentially impacting funding and operations. Increased inflation or interest rates may limit liquidity for capital raising.
• The company may face significant competition from numerous companies developing treatments for NMIBC, including Bristol Myers Squibb and Gilead Sciences. This change emphasizes the competitive landscape and potential market challenges.
• The company may terminate the Executive's employment for Cause, ceasing all payments except Accrued Obligations, tightening employment security.
• Refundable tax credits were moved to direct expenses in 2023, impacting financial reporting. This change may affect future cash flow projections and tax strategies.
• Our accumulated deficit rose to $254.7 million from $199.6 million, indicating increasing financial strain. This trend may raise concerns about long-term sustainability and investor confidence.
• The company plans to file for FDA approval of detalimogene in 2026, a year later than previously anticipated. This delay could affect market entry and investor confidence.
• Incremental stock-based compensation expense of $1.0 million was recognized due to modifications in stock option awards. This could influence financial performance metrics.
• We plan to file a Biologics License Application for detalimogene in mid-2026, a delay from previous expectations. This could impact revenue generation timelines.
• The company has outstanding investment tax credits receivable of $20.3 million as of October 31, 2024. This change indicates potential future tax benefits.
• The company expects cash and cash equivalents of $173.5 million to fund operations for at least the next 12 months. This change highlights liquidity management amid operational challenges.
• The accumulated deficit increased from $199 million in 2023 to $254 million in 2024, indicating ongoing financial challenges.
• The Executive's employment may be terminated for Serious Reason, including material dishonesty or fraud, enhancing accountability.
• The company recognized a total share-based compensation expense of $5,324,000 for the year ended October 31, 2024, up from $3,450,000. This increase may affect profitability assessments.
• We may face significant legal costs from potential lawsuits, impacting financial condition and management focus. Legal proceedings can divert resources and affect operational efficiency.
• Changes in patent laws and the new unitary patent system in Europe may affect our competitive position. Uncertainty in litigation outcomes could impact our ability to commercialize product candidates.
• The Executive agrees not to engage in Competitive Business in the U.S. or Canada during the Restriction Period, protecting company interests.
• Borrower acknowledges that it does not have any defenses against payment obligations under the Existing Loan Agreement, reinforcing the company's commitment to its financial responsibilities.